 AUSTIN, Texas, Feb. 23, 2022 GLOBE NEWSWIRE -- Lumos Pharma, Inc. NASDAQ:LUMO, a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks. 